Strong improvement of 2023 results thanks to sustained commercial activity on Sibnayal®

  • Sibnayal® volume up 84%
  • Gross sales exceed €4 million for the first time
  • Sharp decrease in net loss to -7.03 M€ vs. -11.47 M€ in 2022
  • Year-end cash position at €5.25 million and cash runway extended to Q2 2025
  • Major announcement post-closing: US Orphan Drug Designation of ADV7103 in cystinuria